adenine has been researched along with Anemia in 35 studies
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (25.71) | 18.7374 |
1990's | 4 (11.43) | 18.2507 |
2000's | 3 (8.57) | 29.6817 |
2010's | 13 (37.14) | 24.3611 |
2020's | 6 (17.14) | 2.80 |
Authors | Studies |
---|---|
Gao, M | 1 |
Zhang, Z | 1 |
Zhang, Y | 1 |
Li, M | 1 |
Che, X | 1 |
Cui, X | 1 |
Wang, M | 1 |
Xiong, Y | 1 |
Li, C | 1 |
Huang, H | 1 |
Wang, R | 1 |
Zhang, C | 1 |
Huang, S | 1 |
Wu, J | 1 |
Mo, P | 1 |
Yu, H | 1 |
Li, S | 1 |
Chen, J | 1 |
Yamazaki, D | 2 |
Konishi, Y | 1 |
Morikawa, T | 1 |
Kobara, H | 1 |
Masaki, T | 1 |
Hitomi, H | 2 |
Osafune, K | 1 |
Nakano, D | 3 |
Kittikulsuth, W | 2 |
Nishiyama, A | 3 |
Mei, H | 1 |
Wu, N | 1 |
Huang, X | 1 |
Cui, Z | 1 |
Xu, J | 1 |
Yang, X | 1 |
Zeng, F | 1 |
Wang, K | 1 |
Li, L | 1 |
Zhang, A | 1 |
Morisawa, N | 1 |
Ohsaki, H | 1 |
Suzuki, N | 1 |
Yamamoto, M | 1 |
Bandach, I | 1 |
Segev, Y | 1 |
Landau, D | 1 |
Sinha, R | 1 |
Redekop, WK | 1 |
Rahman, A | 1 |
Sufiun, A | 1 |
Kitada, K | 1 |
Coutre, SE | 1 |
Byrd, JC | 1 |
Hillmen, P | 1 |
Barrientos, JC | 2 |
Barr, PM | 1 |
Devereux, S | 1 |
Robak, T | 1 |
Kipps, TJ | 1 |
Schuh, A | 1 |
Moreno, C | 1 |
Furman, RR | 1 |
Burger, JA | 2 |
O'Dwyer, M | 1 |
Ghia, P | 1 |
Valentino, R | 1 |
Chang, S | 1 |
Dean, JP | 1 |
James, DF | 1 |
O'Brien, SM | 1 |
Ali, BH | 1 |
Al Za'abi, M | 1 |
Ramkumar, A | 1 |
Yasin, J | 1 |
Nemmar, A | 1 |
Kamkuemah, M | 1 |
Kaplan, R | 1 |
Bekker, LG | 1 |
Little, F | 1 |
Myer, L | 1 |
Chanan-Khan, A | 1 |
Cramer, P | 1 |
Demirkan, F | 1 |
Fraser, G | 1 |
Silva, RS | 1 |
Grosicki, S | 1 |
Pristupa, A | 1 |
Janssens, A | 1 |
Mayer, J | 2 |
Bartlett, NL | 1 |
Dilhuydy, MS | 1 |
Pylypenko, H | 1 |
Loscertales, J | 1 |
Avigdor, A | 1 |
Rule, S | 1 |
Villa, D | 1 |
Samoilova, O | 1 |
Panagiotidis, P | 1 |
Goy, A | 1 |
Mato, A | 1 |
Pavlovsky, MA | 1 |
Karlsson, C | 1 |
Mahler, M | 1 |
Salman, M | 1 |
Sun, S | 1 |
Phelps, C | 1 |
Balasubramanian, S | 1 |
Howes, A | 1 |
Hallek, M | 1 |
Adam, Z | 1 |
Pour, L | 1 |
Krejčí, M | 1 |
Ševčíková, S | 1 |
Pourová, E | 1 |
Ševčíková, E | 1 |
Král, Z | 1 |
Vitale, C | 1 |
Ahn, IE | 1 |
Sivina, M | 1 |
Ferrajoli, A | 1 |
Wierda, WG | 1 |
Estrov, Z | 1 |
Konoplev, SN | 1 |
Jain, N | 1 |
O'Brien, S | 1 |
Farooqui, M | 1 |
Keating, MJ | 1 |
Wiestner, A | 1 |
Akchurin, O | 1 |
Sureshbabu, A | 1 |
Doty, SB | 1 |
Zhu, YS | 1 |
Patino, E | 1 |
Cunningham-Rundles, S | 1 |
Choi, ME | 1 |
Boskey, A | 1 |
Rivella, S | 1 |
Hanudel, MR | 1 |
Rappaport, M | 1 |
Gabayan, V | 1 |
Jung, G | 1 |
Salusky, IB | 1 |
Nemeth, E | 1 |
Ganz, T | 1 |
Zaritsky, J | 1 |
Noy, A | 1 |
de Vos, S | 1 |
Thieblemont, C | 1 |
Martin, P | 1 |
Flowers, CR | 1 |
Morschhauser, F | 1 |
Collins, GP | 1 |
Ma, S | 1 |
Coleman, M | 1 |
Peles, S | 1 |
Smith, S | 1 |
Smith, A | 1 |
Munneke, B | 1 |
Dimery, I | 1 |
Beaupre, DM | 1 |
Chen, R | 1 |
Portilla, J | 1 |
Mugyenyi, P | 3 |
Walker, AS | 2 |
Hakim, J | 3 |
Munderi, P | 2 |
Gibb, DM | 2 |
Kityo, C | 2 |
Reid, A | 2 |
Grosskurth, H | 3 |
Darbyshire, JH | 3 |
Ssali, F | 2 |
Bray, D | 2 |
Katabira, E | 3 |
Babiker, AG | 1 |
Gilks, CF | 1 |
Kabuye, G | 1 |
Nsibambi, D | 2 |
Kasirye, R | 1 |
Zalwango, E | 1 |
Nakazibwe, M | 1 |
Kikaire, B | 1 |
Nassuna, G | 1 |
Massa, R | 1 |
Fadhiru, K | 2 |
Namyalo, M | 1 |
Zalwango, A | 1 |
Generous, L | 1 |
Khauka, P | 2 |
Rutikarayo, N | 1 |
Nakahima, W | 1 |
Mugisha, A | 1 |
Todd, J | 1 |
Levin, J | 1 |
Muyingo, S | 1 |
Ruberantwari, A | 1 |
Kaleebu, P | 2 |
Yirrell, D | 2 |
Ndembi, N | 2 |
Lyagoba, F | 2 |
Hughes, P | 1 |
Aber, M | 1 |
Lara, AM | 2 |
Foster, S | 2 |
Amurwon, J | 2 |
Wakholi, BN | 2 |
Whitworth, J | 1 |
Wangati, K | 1 |
Amuron, B | 1 |
Kajungu, D | 1 |
Nakiyingi, J | 1 |
Omony, W | 1 |
Tumukunde, D | 1 |
Otim, T | 1 |
Kabanda, J | 1 |
Musana, H | 1 |
Akao, J | 1 |
Kyomugisha, H | 1 |
Byamukama, A | 1 |
Sabiiti, J | 1 |
Komugyena, J | 1 |
Wavamunno, P | 1 |
Mukiibi, S | 1 |
Drasiku, A | 1 |
Byaruhanga, R | 1 |
Labeja, O | 1 |
Katundu, P | 2 |
Tugume, S | 2 |
Awio, P | 1 |
Namazzi, A | 1 |
Bakeinyaga, GT | 1 |
Katabira, H | 1 |
Abaine, D | 1 |
Tukamushaba, J | 1 |
Anywar, W | 1 |
Ojiambo, W | 1 |
Angweng, E | 1 |
Murungi, S | 2 |
Haguma, W | 1 |
Atwiine, S | 1 |
Kigozi, J | 3 |
Namale, L | 1 |
Mukose, A | 1 |
Mulindwa, G | 1 |
Atwiine, D | 1 |
Muhwezi, A | 1 |
Nimwesiga, E | 1 |
Barungi, G | 1 |
Takubwa, J | 1 |
Mwebesa, D | 1 |
Kagina, G | 1 |
Mulindwa, M | 1 |
Ahimbisibwe, F | 1 |
Mwesigwa, P | 1 |
Akuma, S | 1 |
Zawedde, C | 1 |
Nyiraguhirwa, D | 1 |
Tumusiime, C | 1 |
Bagaya, L | 1 |
Namara, W | 1 |
Karungi, J | 1 |
Kankunda, R | 1 |
Enzama, R | 1 |
Latif, A | 2 |
Robertson, V | 2 |
Chidziva, E | 1 |
Bulaya-Tembo, R | 1 |
Musoro, G | 1 |
Taziwa, F | 1 |
Chimbetete, C | 1 |
Chakonza, L | 1 |
Mawora, A | 1 |
Muvirimi, C | 1 |
Tinago, G | 1 |
Svovanapasis, P | 1 |
Simango, M | 1 |
Chirema, O | 1 |
Machingura, J | 1 |
Mutsai, S | 1 |
Phiri, M | 1 |
Bafana, T | 1 |
Chirara, M | 2 |
Muchabaiwa, L | 2 |
Muzambi, M | 2 |
Mutowo, J | 1 |
Chivhunga, T | 1 |
Chigwedere, E | 1 |
Pascoe, M | 1 |
Warambwa, C | 1 |
Zengeza, E | 1 |
Mapinge, F | 1 |
Makota, S | 1 |
Jamu, A | 1 |
Ngorima, N | 1 |
Chirairo, H | 1 |
Chitsungo, S | 1 |
Chimanzi, J | 1 |
Maweni, C | 1 |
Warara, R | 1 |
Matongo, M | 1 |
Mudzingwa, S | 1 |
Jangano, M | 1 |
Moyo, K | 1 |
Vere, L | 1 |
Mdege, N | 1 |
Machingura, I | 1 |
Ronald, A | 1 |
Kambungu, A | 1 |
Lutwama, F | 1 |
Mambule, I | 1 |
Nanfuka, A | 1 |
Walusimbi, J | 1 |
Nabankema, E | 1 |
Nalumenya, R | 1 |
Namuli, T | 1 |
Kulume, R | 1 |
Namata, I | 1 |
Nyachwo, L | 1 |
Florence, A | 1 |
Kusiima, A | 1 |
Lubwama, E | 1 |
Nairuba, R | 1 |
Oketta, F | 1 |
Buluma, E | 1 |
Waita, R | 1 |
Ojiambo, H | 1 |
Sadik, F | 1 |
Wanyama, J | 1 |
Nabongo, P | 1 |
Oyugi, J | 1 |
Sematala, F | 1 |
Muganzi, A | 1 |
Twijukye, C | 1 |
Byakwaga, H | 1 |
Ochai, R | 1 |
Muhweezi, D | 1 |
Coutinho, A | 1 |
Etukoit, B | 1 |
Gilks, C | 2 |
Boocock, K | 1 |
Puddephatt, C | 1 |
Grundy, C | 1 |
Bohannon, J | 1 |
Winogron, D | 1 |
Burke, A | 1 |
Babiker, A | 2 |
Wilkes, H | 1 |
Rauchenberger, M | 1 |
Sheehan, S | 1 |
Spencer-Drake, C | 1 |
Taylor, K | 1 |
Spyer, M | 1 |
Ferrier, A | 1 |
Naidoo, B | 1 |
Dunn, D | 2 |
Goodall, R | 2 |
Peto, L | 1 |
Nanfuka, R | 1 |
Mufuka-Kapuya, C | 1 |
Pillay, D | 1 |
McCormick, A | 1 |
Weller, I | 1 |
Bahendeka, S | 1 |
Bassett, M | 1 |
Wapakhabulo, AC | 1 |
Gazzard, B | 1 |
Mapuchere, C | 1 |
Mugurungi, O | 1 |
Burke, C | 1 |
Jones, S | 1 |
Newland, C | 1 |
Pearce, G | 1 |
Rahim, S | 1 |
Rooney, J | 1 |
Smith, M | 1 |
Snowden, W | 1 |
Steens, JM | 1 |
Breckenridge, A | 1 |
McLaren, A | 1 |
Hill, C | 1 |
Matenga, J | 1 |
Pozniak, A | 1 |
Serwadda, D | 1 |
Peto, T | 1 |
Palfreeman, A | 1 |
Borok, M | 1 |
Yürük, K | 1 |
Milstein, DM | 1 |
Bezemer, R | 1 |
Bartels, SA | 1 |
Biemond, BJ | 1 |
Ince, C | 1 |
WILLIAMS, AM | 1 |
CHOSY, JJ | 1 |
SCHILLING, RF | 1 |
OBARA, T | 1 |
Valeri, CR | 2 |
Ragno, G | 1 |
Irenge, LM | 1 |
Derclaye, I | 1 |
Heusterspreute, M | 1 |
Gala, JL | 1 |
Philippe, M | 1 |
Lu, X | 1 |
Zhou, A | 1 |
Jin, C | 1 |
Shimizu, M | 1 |
Fujii, H | 1 |
Mizoguchi, H | 1 |
Masuda, M | 1 |
Toyama, K | 1 |
Yoshikawa, O | 1 |
Kawanishi, K | 1 |
Fujimaki, M | 1 |
Arai, M | 1 |
Handa, M | 1 |
Marlewski, M | 1 |
Smolenski, RT | 1 |
Swierczynski, J | 1 |
Rutkowski, B | 1 |
Zydowo, MM | 1 |
Pivacek, LE | 1 |
Palter, M | 1 |
Dennis, RC | 1 |
Yeston, N | 1 |
Emerson, CP | 1 |
Altschule, MD | 1 |
Foussard-Blanpin, O | 2 |
Groussin, P | 1 |
Madgwick, WJ | 1 |
Maclean, N | 1 |
Baynes, YA | 1 |
Nuki, G | 1 |
Lever, J | 1 |
Seegmiller, JE | 1 |
Sims, L | 1 |
Attardi, G | 1 |
Parnas, H | 1 |
Hwang, MI | 1 |
Attardi, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069] | Phase 2 | 199 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346] | Phase 3 | 232 participants (Actual) | Interventional | 2012-08-28 | Completed | ||
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487] | Phase 3 | 269 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090] | Phase 3 | 578 participants (Actual) | Interventional | 2012-09-19 | Completed | ||
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628] | Phase 2 | 63 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population[NCT02393508] | Phase 3 | 60 participants (Anticipated) | Interventional | 2015-09-30 | Enrolling by invitation | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 42 |
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH | 199 |
A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 70 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
Intervention | (Number) |
---|---|
Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
Intervention | Participants (Number) |
---|---|
PCI-32765 | 116 |
Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 71 |
Relapsed/ Refractory | 75.3 |
Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 96.3 |
Relapsed/ Refractory | 73.6 |
Food- Effect | NA |
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 65.1 |
Ibrutinib (Arm B) | 67.7 |
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 4.1 |
Ibrutinib (Arm B) | 42.6 |
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 22.4 |
Ibrutinib (Arm B) | 87.7 |
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | NA |
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | 44.1 |
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) | |
---|---|---|
Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
Ibrutinib (Arm B) | 69.7 | 78.4 |
Ofatumumab (Arm A) | 32.6 | 9.4 |
ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib | 82.4 |
Chlorambucil | 35.3 |
OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | NA |
"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | 18.9 |
The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 45.6 |
Chlorambucil | 20.3 |
In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 84.3 |
Chlorambucil | 45.5 |
The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 27.2 |
Chlorambucil | 11.3 |
In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 77.1 |
Chlorambucil | 42.9 |
Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)
Intervention | milligram per liter (mg/L) (Mean) |
---|---|
Ibrutinib+BR | -0.46 |
Placebo+BR | -0.23 |
"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -2.1 |
Placebo+BR | -4.1 |
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | 0.0 |
Placebo+BR | 0.0 |
The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -4.3 |
Placebo+BR | 4.0 |
FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -0.9 |
Placebo+BR | 0.0 |
Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years
Intervention | Months (Number) |
---|---|
Ibrutinib+BR | 6.5 |
Placebo+BR | 4.6 |
Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 52 |
Placebo+BR | 61 |
The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 0 |
Placebo+BR | 0 |
ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 87.2 |
Placebo+BR | 66.1 |
OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | NA |
Placebo+BR | NA |
MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 28.7 |
Placebo+BR | 5.9 |
PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | 65.12 |
Placebo+BR | 14.32 |
The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on the scale (Mean) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lost weight | Dry mouth | Bruises | Abdominal discomfort | Temperature going up and down | Night sweats | Skin problems | Feel ill | Feel lethargic | Felt slowed down | Limited in planning activities | Worried about health in the future | Trouble with chest infections | Trouble with other infections | Repeated courses of antibiotics | Worried about picking up infection | |
Ibrutinib+BR | 0.1 | 0.3 | 0.1 | 0.1 | 0.1 | -0.6 | 0.4 | 0.1 | 0.1 | 0.3 | 0.2 | 0.0 | 0.2 | 0.7 | 0.9 | 0.3 |
Placebo+BR | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -0.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 |
Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of Participants (Number) | |
---|---|---|
Hemoglobin | Platelets | |
Ibrutinib+BR | 36.7 | 30.8 |
Placebo+BR | 29.1 | 21.8 |
The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Intervention | Percentage of Participants (Mean) |
---|---|
Single Arm, Intent to Treat Population | 46 |
3 reviews available for adenine and Anemia
Article | Year |
---|---|
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou | 2008 |
A clinical experience with ADSOL preserved erythrocytes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Blood Preservation; Blood Transfusion; Blood Transf | 1988 |
7 trials available for adenine and Anemia
Article | Year |
---|---|
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr | 2016 |
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Anemia; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi | 2016 |
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic | 2017 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Transfusion of banked red blood cells and the effects on hemorrheology and microvascular hemodynamics in anemic hematology outpatients.
Topics: Adenine; Aged; Aged, 80 and over; Anemia; Blood Banks; Blood Preservation; Cellular Senescence; Cryo | 2013 |
[Multicenter clinical evaluation of red cell concentrates stored up to 6 weeks in MAP, a new additive solution].
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Blood Component Transfusion; Blood Preservation; Bl | 1992 |
25 other studies available for adenine and Anemia
Article | Year |
---|---|
Steamed Panax notoginseng attenuates renal anemia in an adenine-induced mouse model of chronic kidney disease.
Topics: Adenine; Anemia; Animals; Animals, Outbred Strains; Disease Models, Animal; Dose-Response Relationsh | 2022 |
Jian-Pi-Yi-Shen formula restores iron metabolism from dysregulation in anemic rats with adenine-induced nephropathy.
Topics: Adenine; Anemia; Animals; Fibrosis; Hepcidins; Iron; Rats; Renal Insufficiency, Chronic | 2023 |
Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hematocrit; Hematopoietic Stem Cel | 2020 |
Possible mechanisms by which silkworm faeces extract ameliorates adenine-induced renal anaemia in rats.
Topics: Adenine; Anemia; Animals; Bombyx; Disease Models, Animal; Erythropoietin; Feces; Hepcidins; Humans; | 2021 |
Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Topics: Acute Kidney Injury; Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hypoxia-Induc | 2020 |
Experimental modulation of Interleukin 1 shows its key role in chronic kidney disease progression and anemia.
Topics: Adenine; Anemia; Animals; Antibodies, Monoclonal; Disease Models, Animal; Disease Progression; Immun | 2021 |
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comor | 2018 |
A novel approach to adenine-induced chronic kidney disease associated anemia in rodents.
Topics: Adenine; Anemia; Animals; Blood Urea Nitrogen; Creatinine; Dose-Response Relationship, Drug; Erythro | 2018 |
Anemia in adenine-induced chronic renal failure and the influence of treatment with gum acacia thereon.
Topics: Adenine; Anemia; Animals; Gum Arabic; Kidney Failure, Chronic; Male; Phytotherapy; Random Allocation | 2014 |
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtr | 2015 |
Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Femur; Fibroblast Growth Factor-23; Growth Disorde | 2016 |
Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model.
Topics: Adenine; Anemia; Animals; Blood Urea Nitrogen; Diet; Disease Models, Animal; Erythropoietin; Gene Ex | 2017 |
Effect of vitamin B12 in vitro on incorporation of nucleic acid precursors by pernicious anemia bone marrow.
Topics: Adenine; Anemia; Anemia, Pernicious; Bone Marrow; DNA; Energy Metabolism; In Vitro Techniques; Nucle | 1963 |
[MICROCHEMICAL STUDY OF VARIOUS CELLS USING THE MICROSPECTROPHOTOMETER. II. ON THE RELATIVE AMOUNT OF DNA IN THE BONE MARROW CELLS].
Topics: Adenine; Anemia; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; DNA; Microchemistry; Mitomyc | 1963 |
The effects of preserved red blood cells on the severe adverse events observed in patients infused with hemoglobin based oxygen carriers.
Topics: 2,3-Diphosphoglycerate; Adenine; Adenosine Triphosphate; Anemia; Blood Preservation; Blood Substitut | 2008 |
Beta-thalassaemia in indigenous Belgians: an update.
Topics: Adenine; Amino Acid Substitution; Anemia; Anemia, Hypochromic; Belgium; Beta-Globulins; beta-Thalass | 1997 |
PMPA beats SIV again.
Topics: Adenine; Anemia; Animals; Antiviral Agents; Hemoglobins; Macaca; Organophosphonates; Phosphates; Sim | 1996 |
[The effects of electroporation-mediated erythropoietin (EPO) gene transfer into skeleton muscle on renal anemia].
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Electroporation; Erythropoietin; Gene Expression; | 2000 |
Adenine nucleotide catabolism in the erythrocytes of uraemic patients.
Topics: Adenine; Adenine Nucleotides; AMP Deaminase; Anemia; Erythrocytes; Humans; Hypoxanthine; Hypoxanthin | 1991 |
[Action of tricanthine, a natural derivative of adenine, on the figured elements of the blood of rats made anemic by irradiation].
Topics: Adenine; Anemia; Animals; Blood Cells; Radiation Effects; Rats | 1966 |
[Action of a natural derivative of adenine on the formed elements of the blood in experimental anemia in rabbits induced by blood withdrawal].
Topics: Adenine; Alkaloids; Anemia; Animals; Bloodletting; Erythrocyte Count; Erythrocytes; Leukocyte Count; | 1966 |
RNA synthesis in chicken erythrocytes.
Topics: Adenine; Anemia; Animals; Blood Proteins; Chickens; Dactinomycin; Erythrocyte Count; Erythrocytes; L | 1972 |
Biochemical characteristics of 8-azaguanine resistant human lymphoblast mutants selected in vitro.
Topics: Adenine; Anemia; Azaguanine; Carbon Radioisotopes; Cell Division; Cell Line; Clone Cells; Drug Resis | 1973 |
Drugs used in radiotherapy.
Topics: Adenine; Alkylating Agents; Analgesics; Anemia; Anti-Bacterial Agents; Antiemetics; Antimetabolites; | 1972 |
Giant-size rapidly labeled nuclear ribonucleic acid and cytoplasmic messenger ribonucleic acid in immature duck erythrocytes.
Topics: Adenine; Anemia; Animals; Carbon Isotopes; Cell Nucleus; Chromatography, Ion Exchange; Cytosine; Dac | 1966 |